Literature DB >> 33644104

Interleukin-31 Signaling Bridges the Gap Between Immune Cells, the Nervous System and Epithelial Tissues.

Jana Maria Nemmer1, Marcus Kuchner1, Angeliki Datsi1,2, Péter Oláh1,3, Valérie Julia4, Ulrike Raap5, Bernhard Homey1.   

Abstract

Pruritus represents one of the most common symptoms in dermatology and general medicine. Chronic pruritus severely impairs the quality of life of affected patients. During the last two decades a number of modulators and mediator of pruritus have been identified. Recently, Interleukin (IL)-31 and its receptor complex attracted significant interest, as clinical phase two studies demonstrated therapeutic efficacy of the neutralizing IL-31 receptor A (IL-31RA) antibody nemolizumab in patients suffering from atopic dermatitis or prurigo nodularis. IL-31 has also been shown to play relevant roles in allergic contact dermatitis, urticaria, mastocytosis, allergic rhinitis and asthma. Here, we summarize the current knowledge of the novel cytokine IL-31 and its receptor regarding cellular origin, regulation, signaling pathways and their involvement in biological processes such as pruritus, neuronal growth, inflammation, barrier dysfunction and tissue remodeling.
Copyright © 2021 Nemmer, Kuchner, Datsi, Oláh, Julia, Raap and Homey.

Entities:  

Keywords:  atopic dematitis; interleukin-31; interleukin-31 receptor; neuroinflammation; pruritus

Year:  2021        PMID: 33644104      PMCID: PMC7902767          DOI: 10.3389/fmed.2021.639097

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  75 in total

1.  Increased levels of serum IL-31 in chronic spontaneous urticaria.

Authors:  Ulrike Raap; Dorothea Wieczorek; Manuela Gehring; Inga Pauls; Sonja Ständer; Alexander Kapp; Bettina Wedi
Journal:  Exp Dermatol       Date:  2010-02-16       Impact factor: 3.960

2.  Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.

Authors:  Sonja Ständer; Gil Yosipovitch; Franz J Legat; Jean-Philippe Lacour; Carle Paul; Joanna Narbutt; Thomas Bieber; Laurent Misery; Andreas Wollenberg; Adam Reich; Faiz Ahmad; Christophe Piketty
Journal:  N Engl J Med       Date:  2020-02-20       Impact factor: 91.245

3.  IL-31 Induces Chemotaxis, Calcium Mobilization, Release of Reactive Oxygen Species, and CCL26 in Eosinophils, Which Are Capable to Release IL-31.

Authors:  Nikola Kunsleben; Urda Rüdrich; Manuela Gehring; Natalija Novak; Alexander Kapp; Ulrike Raap
Journal:  J Invest Dermatol       Date:  2015-03-19       Impact factor: 8.551

4.  The Neuropeptide Y Y2 Receptor Is Coexpressed with Nppb in Primary Afferent Neurons and Y2 Activation Reduces Histaminergic and IL-31-Induced Itch.

Authors:  Haisha Ma; Tianle Gao; Jon E T Jakobsson; Hannah M Weman; Bo Xu; Dan Larhammar; Malin C Lagerström
Journal:  J Pharmacol Exp Ther       Date:  2019-11-26       Impact factor: 4.030

5.  Elevated IL-31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180-IgE.

Authors:  Mareen Salz; Stefanie Haeberle; Jochen Hoffmann; Alexander H Enk; Eva N Hadaschik
Journal:  J Dermatol Sci       Date:  2017-08-12       Impact factor: 4.563

6.  Interleukin (IL)-31 activates signal transducer and activator of transcription (STAT)-1, STAT-5 and extracellular signal-regulated kinase 1/2 and down-regulates IL-12p40 production in activated human macrophages.

Authors:  S Kasraie; M Niebuhr; T Werfel
Journal:  Allergy       Date:  2013-04-27       Impact factor: 13.146

7.  The cells and circuitry for itch responses in mice.

Authors:  Santosh K Mishra; Mark A Hoon
Journal:  Science       Date:  2013-05-24       Impact factor: 47.728

8.  Regulated expression of the IL-31 receptor in bronchial and alveolar epithelial cells, pulmonary fibroblasts, and pulmonary macrophages.

Authors:  Randeep S Jawa; Souvik Chattopadhyay; Erin Tracy; Yanping Wang; Kristin Huntoon; Merril T Dayton; Heinz Baumann
Journal:  J Interferon Cytokine Res       Date:  2008-04       Impact factor: 2.607

9.  Cutaneous T-cell Lymphoma and Pruritus: The Expression of IL-31 and its Receptors in the Skin.

Authors:  Leigh A Nattkemper; Maria-Estela Martinez-Escala; Ari B Gelman; Elisha M Singer; Alain H Rook; Joan Guitart; Gil Yosipovitch
Journal:  Acta Derm Venereol       Date:  2016-11-02       Impact factor: 4.437

10.  IL-31-Driven Skin Remodeling Involves Epidermal Cell Proliferation and Thickening That Lead to Impaired Skin-Barrier Function.

Authors:  Brijendra Singh; Anil G Jegga; Kumar S Shanmukhappa; Ramakrishna Edukulla; Gurjit H Khurana Hershey; Mario Medvedovic; Stacey R Dillon; Satish K Madala
Journal:  PLoS One       Date:  2016-08-24       Impact factor: 3.240

View more
  3 in total

Review 1.  Nemolizumab: First Approval.

Authors:  Susan J Keam
Journal:  Drugs       Date:  2022-07-14       Impact factor: 11.431

Review 2.  Interrelationship and Sequencing of Interleukins4, 13, 31, and 33 - An Integrated Systematic Review: Dermatological and Multidisciplinary Perspectives.

Authors:  Alin Laurentiu Tatu; Anca Arbune; Valentin Chioncel; Elena Niculet; Thomas Nadasdy; Carmen Bobeica; Alina Viorica Iancu; Caterina Dumitru; Valentin Tudor Popa; Nicolas Kluger; Victor Gabriel Clatici; Claudiu Ionut Vasile; Cristian Onisor; Alexandru Nechifor
Journal:  J Inflamm Res       Date:  2022-09-08

Review 3.  Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments.

Authors:  Anthony Bewley; Bernard Homey; Andrew Pink
Journal:  Dermatol Ther (Heidelb)       Date:  2022-08-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.